在质母细胞瘤治疗中药物输送系统的进步
Purusottam Mishra1, Payal Gupta2, Aleksandra Markowska3
1Biotechnology Center, Silesian University of Technology, 44-100 Gliwice, Poland.
International journal of molecular sciences
|March 14, 2026
概括
新型药物输送系统通过改善血脑屏障的透和瘤向来治疗侵袭性质母细胞瘤 (GB) 是有前途的. 这些进步提供了更好的生存结果,尽管临床应用仍然存在翻译挑战.
科学领域:
- 神经瘤学神经瘤学
- 纳米医学是一种纳米医学.
- 药物输送系统 药物输送系统
背景情况:
- 质母细胞瘤 (GB) 是一种具有高死亡率的侵袭性脑瘤.
- 挑战包括瘤异质性,侵入性,血脑屏障 (BBB) 和耐药性.
- 目前的手术,放射治疗和temozolomide (TMZ) 化疗等治疗方法由于BBB透率较低而受到限制.
研究的目的:
- 审查用于质母细胞瘤治疗的药物输送平台的最新进展.
- 突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出
- 讨论转化挑战和质母细胞瘤治疗的未来前景.
主要方法:
- 对纳米技术,制药科学和用于GB药物输送的基因工程的最新文献的审查.
- 专注于纳米粒子,水凝,细胞外囊泡和微针.
- 对疗效,BBB透率和生存结果的临床前数据的分析.
主要成果:
- 新型药物输送系统在临床前模型中显示出优越的BBB透率和瘤向性.
- 这些系统有助于控制药物释放,并改善了生存结果.
- 像EGFR,NF-κB和PI3K/Akt/mTOR这样的关键途径与GB的进展有关,并且是这些系统的目标.
结论:
- 先进的药物输送平台为改善质母细胞瘤治疗疗效提供了显著的潜力.
- 克服诸如大规模生产,瘤异质性和非目标效应等挑战对于临床翻译至关重要.
- 将生物决策和瘤应激反应纳入系统设计是未来质母细胞瘤治疗的关键.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:29Drug Delivery: Parenteral Route
2.1K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.1K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:27Drug Delivery Systems: Different Types
166
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
166
01:19Modified-Release Drug Delivery Systems: Overview
97
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
97